|
1. Biologie
|
|
|
Adding Letters to the DNA Alphabet [NIH Director's Blog]
|
|
|
|
|
|
An
extra two letters might not sound like a lot, but it now vastly expands
the number of possible three-letter “words” that can be written in DNA.
In fact, the expanded code boosts the number of possible codons and
corresponding amino acids from 20 to 172! Of course, caution is
warranted.
|
|
|
|
|
|
|
Everything You Need to Know About Crispr Gene Editing [Wired]
|
|
|
|
|
|
Crispr
isn’t perfect; sometimes the protein veers off course and makes cuts at
unintended sites. So scientists are actively working on ways to
minimize these off-target effects. And as it gets better, the ethical
questions surrounding the technology are going to get a lot thornier.
|
|
|
|
|
|
|
4.12 Biopsies liquides
|
|
|
Blood test could predict skin cancer's return [Cancer Research UK]
|
|
|
|
|
|
Led
by researchers based at the Cancer Research UK Manchester Institute
and The Christie NHS Foundation Trust, scientists studied blood samples
taken after surgery from 161 patients with stage 2 and 3 melanoma. They
then looked for faults in two genes that are linked to 70% of melanoma
skin cancers – BRAF and NRAS.
|
|
|
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
|
|
5.1 Traitements - Pré-clinique
|
|
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
5.12.4 Immunothérapies - Essais
|
|
|
|
5.12.7 Immunothérapies - vaccins
|
|
|
|
5.2 Pharma
|
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
|
5.4 Traitements - Economie
|
|
|
NICE says ‘no’ to Novartis’ AML drug Rydapt [PharmaTimes]
|
|
|
|
|
|
“There
is also considerable uncertainty about the cost effectiveness of
midostaurin because of problems with the economic model. These include
not accounting properly for remission after relapse and including
implausibly high long-term costs in some situations,” according to the
consultation document.
|
|
|
|
|
|
|
5.8.2 ASH - Pharma
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.1 Observation
|
|
|
|
6.10 Politiques
|
|
|
|
6.6 Publications
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|